Trial reportJournal of surgical oncology2018
Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.
Trial report in Journal of surgical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04898504 (EXtended CriteriA Treatment for LIver Metastases With Heavy Tumour BURden 1 + 2), which is not on this map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
EXtended CriteriA Treatment for LIver Metastases With Heavy Tumour BURden 1 + 2
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Outcomes of Hepatic Artery-Based Therapies and Systemic Multiagent Chemotherapy in Unresectable Colorectal Liver Metastases: A Systematic Review and Meta-analysis.Annals of surgical oncology · 2024Pooled it
- Review
- Liver Transplantation for Unresectable Colorectal Liver Metastases: Evidence, Patient Selection, and Clinical Implementation.Cancers · 2026Review
- Hepatic Artery Infusion Pump Chemotherapy Associated Biliary Sclerosis After Treatment for Colorectal Cancer Liver Metastasis.Annals of surgical oncology · 2026Article
- The evolving landscape of colorectal liver metastasis management: from resection to transplantation - a narrative review.World journal of surgical oncology · 2026Review
- Article
- Hepatic lymph node metastases in patients with colorectal liver metastases undergoing hepatic artery infusion pump placement.Annals of hepato-biliary-pancreatic surgery · 2026Article
- Retrospective Analysis of HAIP Therapy in Metastatic Colorectal Cancer: Efficacy, Safety, and Prognostic Factors.Journal of gastrointestinal cancer · 2026Article
- Current perspectives and guidelines on liver transplantation for metastatic colorectal cancer.World journal of transplantation · 2025Review
- Review
- Circulating Tumor DNA-Based Selection for Hepatic Artery Infusion Pump Chemotherapy: Primum Non Nocere.Annals of surgical oncology · 2025Article
- Israel's First Port-Based Hepatic Artery Infusion Program: Early Outcomes in Colorectal Liver Metastases.Annals of surgical oncology · 2025Article
- The Landmark Series: Hepatic Arterial Infusion Pump Chemotherapy for Colorectal Liver Metastases and Intrahepatic Cholangiocarcinoma.Annals of surgical oncology · 2025Review
- Combination of Irreversible Electroporation andCancers · 2025Review
- Review
- Minimum Requirements to Safely Establish and Sustain New Hepatic Arterial Infusion Pump Programs: An International Expert Perspective.Annals of surgical oncology · 2025Review
- The Ugly: Metastatic Colon Cancer-Surgical Options.Clinics in colon and rectal surgery · 2025Review
- Robotic Versus Open Placement of Hepatic Artery Infusion Pumps.Annals of surgical oncology · 2025Article
- Hepatic arterial infusion pump chemotherapy for colorectal liver metastases: Revisiting traditional techniques to explore new frontiers.World journal of clinical oncology · 2025Article
- Perioperative and Oncologic Outcomes of Hepatic Arterial Infusion (HAI) Pump Chemotherapy for Patients with Unresectable Colorectal Liver Metastases at an Expanding HAI Program.Annals of surgical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
BACKGROUND/
objectivesCombination hepatic artery infusion (HAI) and systemic (SYS) chemotherapy for unresectable CRLM results in high tumor-response rates. This study represents an update of long-term survival and conversion to resectability in patients with unresectable CRLM treated with HAI and SYS chemotherapy in a phase II study.
methodThe primary endpoint was complete resection. Multivariate and landmark analysis assessed the effect of complete resection on progression-free (PFS) and overall survival (OS).
resultsFrom 2007 to 2012, 64 patients with median of 13 tumors were enrolled; 67% had prior chemotherapy. 33 patients (52%) were converted to resection. Median follow-up among survivors was 81 months. Median PFS and OS were 13 and 38 months, respectively, with 5-year-OS of 36%. Chemotherapy-naïve patients had 5-year-OS of 51%. Conversion to resection was the only independent factor prognostic of improved PFS and OS. Nine of 64 patients (14%) are NED (five since initial resection, three after resection of recurrent disease, one from chemotherapy alone) at median follow-up of 86 months from treatment initiation, and 72 months from last operative intervention.
conclusionCombination HAI and SYS is an effective therapy for high-volume unresectable CRLM, resulting in a high rate of resection, long-term survival, and the potential for cure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.